BEIJING, April 01, 2026–(BUSINESS WIRE)–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Pharmacy; HKEX: 00460).
Under the agreement, both parties will combine Biocytogen’s fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies in multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish long-term strategic partnerships.
Sihuan Pharmaceutical greatly appreciates the power of Biocytogen’s technology platform. In this collaboration, Biocytogen will leverage its integrated platform, including a proprietary target-humanized mouse model and live efficacy system, as well as an AI-driven antibody discovery platform built on real human antibody sequences, to support the development of novel antibody therapeutics. By combining the complementary strengths of both parties, the partnership aims to accelerate the progress of promising molecules towards clinical and commercial success.
Dr. Yuelei Shen, President and CEO of Biocytogen, stated: “We are pleased to establish this strategic partnership with Sihuan Pharmaceutical. Leveraging our proprietary platform, Biocytogen has built a comprehensive pipeline of next-generation therapeutic modalities, including bispecific and multispecific antibodies, ADCs, VHHs, and TCR to further expand our joint disease efforts. and further demonstrate strong industry recognition for our technology platform.”
About Biocytogen
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that conducts research and development of novel antibody-based drugs with innovative technologies. Established in gene editing technology, Biocytogen has established a dual-engine platform combining a full human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerate global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platform for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for 100,00 human antibody sequences against over 1000 targets for worldwide collaboration. By December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—through co-development, out-licensing, and transfer—have been created globally, including landmark partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of humanized knock-in model drug targets for preclinical research, and now provides several thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
#Biocytogen #Sihuan #Pharmaceutical #Announce #Strategic #Partnership #weight #loss